NASDAQ:CRBU Caribou Biosciences (CRBU) Stock Price, News & Analysis $1.54 -0.09 (-5.25%) As of 02:46 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Caribou Biosciences Stock (NASDAQ:CRBU) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Caribou Biosciences alerts:Sign Up Key Stats Today's Range$1.53▼$1.6350-Day Range$1.46▼$1.9452-Week Range$1.38▼$3.54Volume738,680 shsAverage Volume1.52 million shsMarket Capitalization$164.56 millionP/E RatioN/ADividend YieldN/APrice Target$7.75Consensus RatingModerate Buy Company Overview Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis. Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology. The company holds licenses to foundational CRISPR intellectual property from the University of California, enabling continuous innovation in genome engineering. Since completing its initial public offering in August 2021, Caribou has focused on progressing its clinical pipeline and expanding manufacturing capabilities to support its growing roster of investigational therapies. Caribou’s leadership team combines deep expertise in molecular biology, clinical development and manufacturing scale-up, supported by an advisory board that includes leading figures in biotechnology and medicine. The company has established strategic collaborations with pharmaceutical and academic partners to advance its research programs and accelerate clinical translation. Caribou continues to conduct trials across multiple regions, aiming to bring its next-generation cell therapies and in vivo gene-editing treatments to patients worldwide.AI Generated. May Contain Errors. Read More Caribou Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreCRBU MarketRank™: Caribou Biosciences scored higher than 40% of companies evaluated by MarketBeat, and ranked 705th out of 917 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingCaribou Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCaribou Biosciences has a consensus price target of $7.75, representing about 401.6% upside from its current price of $1.55.Amount of Analyst CoverageCaribou Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Caribou Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Caribou Biosciences are expected to decrease in the coming year, from ($0.88) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Caribou Biosciences is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Caribou Biosciences is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCaribou Biosciences has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Caribou Biosciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.71% of the float of Caribou Biosciences has been sold short.Short Interest Ratio / Days to CoverCaribou Biosciences has a short interest ratio ("days to cover") of 11.95, which indicates bearish sentiment.Change versus previous monthShort interest in Caribou Biosciences has recently increased by 7.10%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCaribou Biosciences does not currently pay a dividend.Dividend GrowthCaribou Biosciences does not have a long track record of dividend growth. News and Social Media3.7 / 5News SentimentN/A News SentimentCaribou Biosciences has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.98 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Caribou Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for CRBU on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows4 people have added Caribou Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Caribou Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders8.54% of the stock of Caribou Biosciences is held by insiders.Percentage Held by Institutions77.51% of the stock of Caribou Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Caribou Biosciences' insider trading history. Receive CRBU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Caribou Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRBU Stock News HeadlinesCRBU Q3 EPS Estimate Raised by Brookline Capital MarketsAugust 20, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Caribou Biosciences (CRBU) and Aveanna Healthcare Holdings (AVAH)August 15, 2026 | theglobeandmail.comBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.August 31 at 1:00 AM | Chaikin Analytics (Ad)Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 13, 2026 | globenewswire.comCaribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceJune 29, 2026 | globenewswire.comCaribou Biosciences Shareholders Decide Key Governance MattersJune 18, 2026 | tipranks.comCaribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026June 11, 2026 | globenewswire.comCaribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual MeetingJune 11, 2026 | globenewswire.comSee More Headlines CRBU Stock Analysis - Frequently Asked Questions How have CRBU shares performed this year? Caribou Biosciences' stock was trading at $1.59 at the start of the year. Since then, CRBU stock has decreased by 2.8% and is now trading at $1.5450. How were Caribou Biosciences' earnings last quarter? Caribou Biosciences, Inc. (NASDAQ:CRBU) issued its quarterly earnings results on Thursday, August, 13th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.08. The firm earned $1.50 million during the quarter, compared to analyst estimates of $2.28 million. Caribou Biosciences had a negative net margin of 1,030.42% and a negative trailing twelve-month return on equity of 89.11%. When did Caribou Biosciences IPO? Caribou Biosciences (CRBU) raised $285 million in an initial public offering on Wednesday, July 21st 2021. The company issued 19,000,000 shares at $14.00-$16.00 per share. Who are Caribou Biosciences' major shareholders? Top institutional investors of Caribou Biosciences include BlackRock Inc. (7.88%), Bank of America Corp DE (1.42%), GSA Capital Partners LLP (0.47%) and Green Alpha Advisors LLC (0.37%). Insiders that own company stock include Rachel E Haurwitz, Barbara G Mcclung, Ruhi Ahmad Khan, Timothy P Kelly, Tina M Albertson and Sriram Ryali. View institutional ownership trends. How do I buy shares of Caribou Biosciences? Shares of CRBU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Caribou Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Caribou Biosciences investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/13/2026Today8/31/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5d) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 As of 5 days ago, CRBU's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CRBU CIK1619856 Webcariboubio.com Phone510-982-6030FaxN/AEmployees100Year Founded2012Price Target and Rating Average Price Target for Caribou Biosciences$7.75 High Price Target$11.00 Low Price Target$5.00 Potential Upside/Downside+404.9%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$148.12 million Net Margins-1,030.42% Pretax Margin-1,035.90% Return on Equity-89.11% Return on Assets-62.47% Debt Debt-to-Equity RatioN/A Current Ratio6.49 Quick Ratio6.49 Sales & Book Value Annual Sales$10.04 million Price / Sales16.40 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book1.17Miscellaneous Outstanding Shares107,208,000Free Float98,052,000Market Cap$164.56 million OptionableOptionable Beta2.38 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:CRBU) was last updated on 8/31/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caribou Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caribou Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
